Thalidomide-induced toxic epidermal necrolysis

Pharmacotherapy

Volumn 19, Issue 10, 1999, Pages 1177-1180

  Horowitz, Sandra B ^a   Stirling, Alexandra L ^a  

^a ST JOHN'S UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; BISOPROLOL; CARBOPLATIN; CARMUSTINE; DEXAMETHASONE; DIPHENHYDRAMINE; FAMOTIDINE; GENTAMICIN; HYDROXYZINE; LORAZEPAM; MORPHINE SULFATE; NIZATIDINE; PHENOBARBITAL; PHENYTOIN; POTASSIUM CHLORIDE; SILVER NITRATE; THALIDOMIDE; VALPROATE SEMISODIUM; VANCOMYCIN;

ADULT; ANXIETY NEUROSIS; ARTICLE; CASE REPORT; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSENSITIVITY REACTION; HYPOKALEMIA; IMMUNE DEFICIENCY; INTRAVENOUS DRUG ADMINISTRATION; MORTALITY; ORAL DRUG ADMINISTRATION; PAIN; RASH; SEIZURE; SEPSIS; SKIN DISEASE; TOPICAL DRUG ADMINISTRATION; TOXIC EPIDERMAL NECROLYSIS;

ANGIOGENESIS INHIBITORS; EPIDERMAL NECROLYSIS, TOXIC; FEMALE; GLIOBLASTOMA; HUMANS; HYPERSENSITIVITY; MIDDLE AGED; THALIDOMIDE;

EID: 0032858116     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.19.15.1177.30571     Document Type: Article

References (22)

1. Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995;333:1600-7.
2. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994;331:1272-85.
3. Heimbach DM, Engrav LH, Marvin JA, Harnar TJ, Grobe BJ. Toxic epidermal necrolysis, a step forward in treatment. JAMA 1987;257:2171-5.
4. Pruitt BA Jr. Burn treatment for the unburned. JAMA 1987;257:2207-8.
5. Revuz J, Penso D, Roujeau JC, et al. Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients. Arch Dermatol 1987;123(9):1160-5.
6. Haslett P, Tramontana J, Burroughs M, Hempstead M, Kaplan G. Adverse reactions to thalidomide in patients infected with human immunodeficiency virus. Clin Infect Dis 1997;24(6):1223-7.
7. Tseng S, Pak KG, Washenik K, Pomeranz MK, Shupack JL. Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses. J Am Acad Dermatol 1996;35:969-79.
8. Vanchieri C. Preparing for thalidomide's comeback. Ann Intern Med 1997;127(10):951-2.
9. Günzler V. Thalidomide in human immunodeficiency virus (HIV) patients: a review of safety considerations. Drug Saf 1992;7(2):116-34.
10. AJHP News. Thalidomide approval brings tight restrictions on access. Am J Health-Syst Pharm 1998;55:1746;49.
11. Celgene. EntreMed Inc. receives orphan drug designation from the FDA for thalidomide in brain malignancies. Company press release. Warren, NJ;March 1998.
12. Celgene. EntreMed Inc. reports successful interim results in cancer phase 11 clinical trial for thalidomide. Company press release. Warren, NJ;May 1998.
13. Moreira AL, Sampaio EP, Zmuidzinas A, Frindt P, Smith KA, Kaplan G. Thalidomide exerts its inhibitory action on tumor necrosis factor-alpha by enhancing mRNA degradation. J Exp Med 1993;177:1675-80.
14. Wolkenstein P, Latarjet J, Roujeau JC, et al. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet 1998;352:1586-9.
15. Williams I, Weller IVD, Malni A, Anderson J, Waters MF. Thalidomide hypersensitivity in AIDS. Lancet 1991;337:436-7.
16. Haslett P, Hempstead M, Seidman C, et al. The metabolic and immunologic effects of short-term thalidomide treatment of patients infected with the human immunodeficiency virus. AIDS Res Hum Retroviruses 1997;13(12):1047-54.
17. Eisenbud L, Horowitz I, Kay B. Recurrent aphthous stomatitis of the Behçet's type: successful treatment with thalidomide. Oral Surg Oral Med Oral Pathol 1987;64:289-92.
18. Bielsa I, Teixido J, Ribera M, Ferrandiz C. Erythroderma due to thalidomide: report of two cases. Dermatology 1994;189(2):179-81.
19. Micromedex, Inc. Drug evaluations [monograph on CD-ROM]. Englewood, CO: Micromedex, 1998.
20. Fine HA, Loeffler JS, Kyritsis A, et al. A phase II trial of the anti-angiogenic agent, thalidomide, in patients with recurrent high-grade gliomas [abstr]. Proc Am Soc Clin Oncol 1997;16:A1372.
21. Celgene. Thalomid (thalidomide) package insert. Warren, NJ;1998.
22. Bayard PJ, Berger TG, Jacobson MA. Drug hypersensitivity reaction and human immunodeficiency virus disease. J Acquir Immune Defic Syndr 1992;5(12):1237-57.